Welcome to our dedicated page for COPRF news (Ticker: COPRF), a resource for investors and traders seeking the latest updates and insights on COPRF stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect COPRF's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of COPRF's position in the market.
Medivolve Inc. (OTC:COPRF) announces the launch of new COVID-19 testing centers in Texas, Florida, and North Carolina, expanding its network to 62 sites. In January, the company sold 73,973 COVID-19 tests at an average price of $96, with 52% cash pay sales. A webinar on February 4 will discuss recent developments, featuring CEO Doug Sommerville. Medivolve is also acquiring up to 40% of Marvel Diagnostics for up to $1 million to enhance its testing capabilities. The company emphasizes the importance of increased testing for combating COVID-19.
Medivolve Inc. (OTC:COPRF) is hosting a webinar on February 4 at 1 PM ET to discuss recent developments, including the growth of its COVID-19 testing network and a special presentation on the BlowFISH Technology from UCLA researchers. Medivolve has signed a share purchase agreement to acquire up to 40% of Marvel Diagnostics for up to US$1 million, targeting clinical studies for BlowFISH. This system aims to replace traditional swabbing with a more efficient method. However, Medivolve cautions about the early-stage nature of this research.